Completed

Study Description:

Phase II, randomised, controlled study to evaluate the immunigenicity, reactogenicity and safety of Priorix vaccine produced using the modified Mumps manufactering process and containing no HSA (Priorix-MMP/mf) compared to the currently licenced Priorix and Merck and Co.'s M-M-RII vaccines when administered as a primary vaccination to healthy children aged 12-24 months

GSK Study ID:

104420


Has Results Document Available
ClinicalTrials.gov Identifier:

Not Available


EudraCT Number:

Not Available


Study Overview

Medical Conditions

Measles, Mumps and Rubella (MMR)

Product

SB209762

Collaborators

N/A


Date

July 2005 to October 2005

Type

N/A

Phase

2/3


Gender

N/A

Age

N/A

Accepts Healthy Volunteers

N/A


Locations


Study Design

  • Primary Purpose: Not Available
  • Allocation: Not Available
  • Study Design: Not Available
  • Study Classification: Not Available
  • Masking: Not Available
  • Masked Subject: Not Available
  • Masked Caregiver: Not Available
  • Masked Investigator: Not Available
  • Masked Assessor: Not Available
Inclusion / Exclusion Criteria: Click to view inclusion/exclusion criteria:
Enrollment: